Primary prevention with β-blockers and ACEIs has also been studied in patients with HER-2–positive breast cancer treated with trastuzumab as part of the MANtICORE (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) trial. This evidence concerns the gene ERBB2 and breast carcinoma.